Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, despite the challenging circumstances, because that familiar routine of phone calls, Zoom and Skype meetings and deadlines has predictably returned. What can you do? The world somehow keeps spinning. To cope, yes, we are quaffing mandatory cups of stimulation. Our choice today is cinnamon dolce. Meanwhile, here are some tidbits to get you started. Hope your day goes well, and do keep in touch. …

Food and Drug Administration Commissioner Stephen Hahn is willing to fast-track a Covid-19 vaccine before clinical trials are complete if it is deemed “appropriate,” Reuters writes, citing a report in The Financial Times. Hahn stressed politics would not play a part. “This is going to be a science, medicine, data decision. … It is up to the [vaccine developer] to apply for authorization or approval, and we make an adjudication of their application. If they do that before the end of Phase 3, we may find that appropriate. We may find that inappropriate, we will make a determination.”

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy